Clinical trials: EoE
Eosinophilic Esophagitis (EoE)
OBS in Adolescent and Adults With EOE: A Phase II, Randomized, Double-Blind, Placebo Controlled, Study With an Open Label Extension
This is a clinical trial to test an experimental drug for the treatment of Eosinophilic Esophagitis (EoE)
- Trial name
- NCT01642212
- Testing
- Oral Budesonide Suspension (MB-9)
- Where
- 23 sites in United States
- Volunteers
- 93 people
- Sponsor
- Shire
Eosinophilic Gastritis, Eosinophilic Gastroenteritis
An Extension Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Duodenitis
This is a Phase 2, open-label, extension study to assess the safety and tolerability of AK002, given monthly for up to 26 doses.
- Conditions
- Eosinophilic Gastritis, Eosinophilic Gastroenteritis, Eosinophilic Duodenitis
- Trial name
- NCT03664960
- Testing
- AK002
- Where
- 17 sites in United States
- Volunteers
- 58 people
- Sponsor
- Allakos Inc.
Ulcerative Colitis, Crohn Disease
Systems Biology of Gastrointestinal and Related Diseases
This is a longitudinal observational study on patients with gastrointestinal and related disease. The study will be conducted for at least 10 years, following each participant over time, as they either go through relapses and…
- Conditions
- Ulcerative Colitis, Crohn Disease, Obesity, Colon Polyp
- Trial name
- NCT05579444
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Viome
Eosinophilic Esophagitis
Study of Dupilumab in Adult Participants With Active Eosinophilic Esophagitis (EoE)
The primary objective of the study is to assess the clinical efficacy of repeat subcutaneous (SC) doses of dupilumab, compared with placebo, to relieve symptoms in adult participants with active, moderate to severe Eosinophilic…
- Trial name
- NCT02379052
- Testing
- Dupilumab
- Where
- 14 sites in United States
- Volunteers
- 47 people
- Sponsor
- Regeneron Pharmaceuticals
Eosinophilic Esophagitis
Expanded Access Protocol for Patients With Eosinophilic Esophagitis
This expanded access program is an open-label, single-arm design where consenting patients may participate up until APT-1011 is commercially available in the relevant regions or the protocol is terminated by the Sponsor.
- Trial name
- NCT05095116
- Testing
- APT-1011 3 mg HS
- Where
- 35 sites in United States
- Sponsor
- Ellodi Pharmaceuticals, LP
Eosinophilic Esophagitis
Safety and Tolerability Study of Oral EUR-1100 to Treat Eosinophilic Esophagitis
Eosinophilic esophagitis (EoE) is an inflammatory disease of the esophagus, characterized by eosinophilic infiltration and gastrointestinal (GI) symptoms.
- Trial name
- NCT01386112
- Testing
- EUR-1100
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- Forest Laboratories
Oesophagitis, Eosinophilic
Intravenous Mepolizumab In Children With Eosinophilic Esophagitis
This study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous mepolizumab in pediatric subjects with eosinophilic esophagitis.
- Trial name
- NCT00358449
- Testing
- mepolizumab
- Where
- 29 sites in United States, Australia and 2 more
- Volunteers
- 84 people
- Sponsor
- GlaxoSmithKline
Eosinophilic Esophagitis
Maintenance of Remission With Budesonide Orodispersible Tablets vs. Placebo in Eosinophilic Esophagitis
The purpose of this study is to prove the superiority of a 48-weeks treatment with budesonide orodispersible tablets versus placebo for the maintenance of clinico-pathological remission in patients with eosinophilic esophagitis.
- Trial name
- EOS-2 (NCT02493335)
- Testing
- Budesonide 0.5mg orodispersible tablet twice daily, Budesonide 1mg orodispersible tablet twice daily
- Where
- Germany
- Volunteers
- 204 people
- Sponsor
- Dr. Falk Pharma GmbH
Eosinophilic Esophagitis
Budesonide Effervescent Tablets vs. Viscous Budesonide Suspension vs. Placebo in Eosinophilic Esophagitis
The purpose of this study is to assess the efficacy of a low and high dose of a budesonide effervescent tablet and oral viscous budesonide suspension vs. placebo for the induction treatment of active eosinophilic esophagitis.
- Trial name
- NCT02280616
- Testing
- low dose budesonide tablet, high dose budesonide tablet, high dose budesonide suspension
- Where
- Germany
- Volunteers
- 76 people
- Sponsor
- Dr. Falk Pharma GmbH
Eosinophilic Esophagitis
A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Esophagitis
This is a Phase 2/3, multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of lirentelimab (AK002) given monthly for 6 doses in adult and adolescent patients with active eosinophilic…
- Trial name
- KRYPTOS (NCT04322708)
- Testing
- lirentelimab (AK002)
- Where
- 78 sites in United States, Australia and 1 more
- Volunteers
- 277 people
- Sponsor
- Allakos Inc.
Eosinophilic Esophagitis
Proof of Concept Study of OC000459 in Eosinophilic Esophagitis
This will be a randomised, double blind, placebo controlled, parallel group evaluation of the effect of OC000459 given orally for eight weeks on active eosinophilic esophagitis.
- Trial name
- NCT01056783
- Testing
- OC000459
- Where
- Switzerland
- Volunteers
- 26 people
- Sponsor
- Oxagen Ltd
Eosinophilic Esophagitis
A Study to Investigate Safety and Tolerability of NDX-3315 and NDX-3324 in Healthy Participants and Patients With Eosinophilic Esophagitis
An open-label phase 2 study to assess the safety and exploratory diagnostic performance of the oral radiopharmaceutical agent NDX-3315 and NDX-3324 in healthy participants and patients with eosinophilic esophagitis (EoE).
- Trial name
- NCT05757856
- Testing
- NDX-3315, NDX-3324, SPECT/CT Imaging
- Where
- 3 sites in United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- NexEos Diagnostics, Inc.
Eosinophilic Esophagitis
Mesalazine Oral Suspension in Active Eosinophilic Esophagitis
Pilot study to assess a mesalazine oral suspension in active eosinophilic esophagitis
- Trial name
- NCT05488405
- Testing
- Mesalamine Oral Product
- Where
- Switzerland
- Volunteers
- 5 people
- Sponsor
- Dr. Falk Pharma GmbH
Ewing's Sarcoma, Primitive Neuroectodermal Tumor (PNET)
Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy
This is a phase II Multicenter, Open-label, Clinical and Pharmacokinetic Study of Zalypsis® (PM00104) in Patients with Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One…
- Conditions
- Ewing's Sarcoma, Primitive Neuroectodermal Tumor (PNET), Askin's Tumor of the Chest Wall, Extraosseous Ewing's Sarcoma (EOE)
- Trial name
- NCT01222767
- Testing
- Zalypsis
- Where
- 7 sites in United States, France and 1 more
- Volunteers
- 17 people
- Sponsor
- PharmaMar
Eosinophilic Esophagitis
Pharmacokinetics, Efficacy, Tolerability and Safety of Different Budesonide Oral Gel Doses in Adults' Subjects of Both Genders With Eosinophilic Esophagitis (EoE)
A phase I/II, multicenter, double-blind, parallel, randomized trial to assess pharmacokinetics, efficacy, tolerability and safety of different budesonide oral gel doses in adults subjects of both genders with eosinophilic…
- Trial name
- BESIDE (NCT05214599)
- Testing
- Budesonide Gel
- Sponsor
- Bazell Pharma AG
Eosinophilic Esophagitis
A Study Evaluating Potential Disease-Mediated Drug-Drug Interaction in Adult Participants With Active Eosinophilic Esophagitis Receiving Cendakimab
The purpose of this study to evaluate the potential for disease-mediated drug-drug interactions between cendakimab and selected substrates of metabolic enzymes in eosinophilic esophagitis participants.
- Trial name
- NCT05175352
- Testing
- Cendakimab, CYP substrates
- Where
- 12 sites in United States
- Volunteers
- 16 people
- Sponsor
- Celgene
Eosinophilic Esophagitis (EoE)
Dose-Ranging Study of Oral Viscous Budesonide in Pediatrics With Eosinophilic Esophagitis
This is a randomized, placebo-controlled, parallel-arm, dose-ranging study in subjects with eosinophilic esophagitis, 2-18 years of age. Eligible subjects will be randomized into one of four treatment groups.
- Trial name
- NCT00762073
- Testing
- budesonide
- Where
- 20 sites in United States
- Volunteers
- 82 people
- Sponsor
- Shire
Eosinophilic Esophagitis
Efficacy and Safety APT-1011 in Adolescent Subjects With Eosinophilic Esophagitis (EoE) - A Sub-Study of the FLUTE-2 Trial
This is a randomized, double-blind, placebo-controlled study of APT-1011, followed by an open-label extension (OLE) in adolescents (≥12 to <18 years) with EoE.
- Trial name
- FLUTEEN (NCT05083312)
- Testing
- APT-1011
- Where
- 3 sites in United States, Australia
- Volunteers
- 6 people
- Sponsor
- Ellodi Pharmaceuticals, LP
Eosinophilic Esophagitis (EoE)
Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE)
The Primary objective is to demonstrate the efficacy of dupilumab treatment compared with placebo in pediatric patients with active eosinophilic esophagitis (EoE) based on histologic improvement meeting validated histologic…
- Trial name
- EoE KIDS (NCT04394351)
- Testing
- Dupilumab
- Where
- 27 sites in United States, Canada
- Volunteers
- 102 people
- Sponsor
- Regeneron Pharmaceuticals
Eosinophilic Esophagitis (EoE)
Trial of Partial Enteral Nutrition With Dairy Free Diet in Eosinophilic Esophagitis
This study aims to introduce a new dietary therapy for Eosinophilic Esophagitis (EoE) patients by using partial enteral nutrition (PEN) to enhance remission rates and explore how this approach affects immune function, gut…
- Trial name
- NCT07234825
- Testing
- Partial enteral nutrition (PEN) with dairy elimination, Dairy elimination alone
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Kate Farms Inc